Ehp Funds Inc. Vertex Pharmaceuticals Inc Transaction History

Ehp Funds Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $81,538 - $89,216	-200 Reduced 11.11%	1,600 $668,000
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $171,500 - $205,340	-500 Reduced 21.74%	1,800 $732,000
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $67,636 - $72,492	200 Added 9.52%	2,300 $799,000
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $352,150 - $394,139	-1,120 Reduced 34.78%	2,100 $739,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $184,099 - $210,015	-650 Reduced 16.8%	3,220 $1.01 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $11,430 - $12,859	40 Added 1.04%	3,870 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.05 Million - $1.17 Million	3,830 New	3,830 $1.11 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Ehp Funds Inc., based on Form 13F filings with the SEC.

Stay updated on Ehp Funds Inc. with notifications on news.